API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Evenity (romosozumab)-treated patients achieved greater increases in cortical volumetric BMD (CvBMD), cortical thickness (Cth), cortical surface BMD (CsBMD) and trabecular volumetric BMD (TvBMD) than comparator groups, from as early as Month 6 through to Month 12.
Lead Product(s): Romosozumab
Therapeutic Area: Musculoskeletal Product Name: Evenity
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Amgen Inc
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 09, 2022
Details:
The results showed that within 12 months of treatment with romosozumab, most patients achieved the STEs for any reduction in fracture risk. At both 12 and 24 months, higher proportions of patients met the STEs with romosozumab compared to alendronate for all fracture types.
Lead Product(s): Romosozumab
Therapeutic Area: Musculoskeletal Product Name: Evenity
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 31, 2022